SG Americas Securities LLC Acquires 34,670 Shares of Standard BioTools Inc. (NASDAQ:LAB)

SG Americas Securities LLC lifted its position in Standard BioTools Inc. (NASDAQ:LABFree Report) by 34.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,927 shares of the company’s stock after buying an additional 34,670 shares during the period. SG Americas Securities LLC’s holdings in Standard BioTools were worth $238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Wolverine Trading LLC bought a new stake in shares of Standard BioTools during the 3rd quarter valued at $27,000. Nisa Investment Advisors LLC grew its position in Standard BioTools by 433.8% in the third quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock worth $35,000 after acquiring an additional 14,732 shares in the last quarter. Creative Planning purchased a new stake in Standard BioTools during the 3rd quarter valued at $39,000. Algert Global LLC purchased a new position in shares of Standard BioTools during the 2nd quarter worth about $44,000. Finally, Simon Quick Advisors LLC bought a new stake in shares of Standard BioTools during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analysts Set New Price Targets

Separately, TD Cowen decreased their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.

View Our Latest Stock Report on Standard BioTools

Standard BioTools Price Performance

Shares of LAB stock opened at $1.42 on Friday. Standard BioTools Inc. has a 1-year low of $1.21 and a 1-year high of $3.04. The company has a market cap of $528.61 million, a P/E ratio of -2.00 and a beta of 1.57. The stock’s 50-day moving average is $1.81 and its 200 day moving average is $1.87.

Standard BioTools Company Profile

(Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

Featured Articles

Want to see what other hedge funds are holding LAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Standard BioTools Inc. (NASDAQ:LABFree Report).

Institutional Ownership by Quarter for Standard BioTools (NASDAQ:LAB)

Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.